The study - the largest and most definitive to date completed in a joint effort with the Radiation Therapy Oncology Group (RTOG) - shows that tumor HPV status is a strong and independent prognostic factor for survival for these patients. Follow-up data from the study were presented today at the 44th annual meeting of the American Society of Clinical Oncology (Abstract #5510).
"This is the strongest prognostic factor we have ever identified for head and neck cancer patients," said K. Kian Ang, M.D., Ph.D., professor in MD Anderson's Department of Radiation Oncology and lead author on the paper. "Its value is stronger than other prognostic factors we have used such as the size of the tumor or presence of tumor in lymph nodes. Knowing that the tumor is associated with HPV is telling the patient that the prognosis is excellent with currently available treatments."
The Phase III clinical trial established by the RTOG examined overall survival and progression-free survival in 323 patients with stage III-IV oropharyngeal cancer treated with a combination of radiation therapy and chemotherapy. Of these patients, 206 had HPV-positive tumors and 117 were HPV-negative. The three-year overall survival rate for patients with HPV-positive tumors was 82.4 percent compared to 57.1 percent with HPV-negative cancer. Progression-free survival rates were 73.7 percent and 43.4 percent, respectively.
When researchers adjusted for other significant determinants of survival, including patient age, race, tumor and nodal stage and tobacco use, patients with HPV-positive cancer had a 58 percent reduction in risk of death relative to patients with HPV-negative tumors. The study noted tobacco use substantially increased risk of death. Results will allow physicians to stratify patients enrolled in clinical trials into low, intermediate or high-risk of death based on HPV status, tobacco use and cancer stage. This information can then be used to better determine which patients are candidates for more intensive investigational therapies.
Oropharyngeal cancer develops in the part of the throat just behind the mouth. The American Cancer Society estimates that 28,500 people in the United States are diagnosed with cancer of the oral cavity and oropharynx each year. While the incidence of head and neck cancer has been declining during the past 30 years, the rate of HPV-positive oropharyngeal cancer is rapidly rising. Today, nearly 70 percent of oropharynx cancer cases are HPV-positive.
Ang credits the strength of the study to its size and the importance of collaboration among investigators. "Even large cancer centers like MD Anderson cannot do these types of studies alone. Working with our collaborators including, Maura Gillison, M.D., Ph.D., professor of medicine, epidemiology and otolaryngology at The Ohio State University, an experienced investigator on the role of HPV in head and neck cancer and co-author on the study, we were able to build on what smaller studies have suggested and produce numbers large enough to examine HPV status together with other prognostic factors."
Head and neck tumors are routinely tested for HPV at MD Anderson and other large institutions. While it remains unclear why patients with HPV-positive tumors have better outcomes than those with HPV-negative tumors, researchers speculate it may be due to biologic and immunologic properties that render HPV-positive cancers inherently less malignant or better able to respond to treatment. Ang notes future studies are warranted to determine how the HPV vaccine, made available to the public in 2006, affects the incidence of HPV-related head and neck cancers.
In addition to Ang and Gillison, other authors on the study include: Randal Weber, M.D., Department of Head and Neck Surgery, David Rosenthal, M.D., Department of Radiation Oncology, Charles Lu, M.D., Department of Thoracic/Head and Neck Medical Oncology, all from MD Anderson; Jonathan Harris, M.S., RTOG Statistical Center; Richard Wheeler, M.D., Huntsman Cancer Institute; Phuc Nguyen-Tan, M.D., entra Hospitaler de L'Universite de Montreal; William Westra, M.D., The Johns Hopkins University; Christine Chung, M.D., Vanderbilt University School of Medicine; Richard Jordan, D.D.S., Ph.D., The University of California at San Francisco; Rita Axelrod, M.D., Thomason Jefferson University Hospital; Craig Silverman, M.D., University of Louisville, Kevin Redmond, M.D., University of Cincinnati College of Medicine.
The RTOG is a multi-institutional international clinical cooperative group funded primarily by National Cancer Institute grants CA21661 and CA37422. RTOG comprises 300 major research institutions in the United States, Canada and internationally.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 40 comprehensive cancer centers designated by the National Cancer Institute. For six of the past eight years, including 2010, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.
Lindsay Anderson | EurekAlert!
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences